Carbonyl reductase 1 as a novel target of (−)‐epigallocatechin gallate against hepatocellular carcinoma
Weixue Huang, Liya Ding, Qiang Huang, Hairong Hu, Shan Liu, Xianmei Yang, Xiaohui Hu, Yongjun Dang, Suqin Shen, Jie Li, Xiaona Ji, Songmin Jiang, Jun O. Liu, Long Yu – 23 July 2010 – Human carbonyl reductase 1 (CBR1) converts the antitumor drug and anthracycline daunorubicin (DNR) into the alcohol metabolite daunorubicinol (DNROL) with significantly reduced antitumor activity and cardiotoxicity, and this limits the clinical use of DNR. Inhibition of CBR1 can thus increase the efficacy and decrease the toxicity of DNR.